Dr. Jörg Schickert

Dr. Jörg Schickert

Partner
Munich

Email joerg.schickert@​hoganlovells.com

Phone +49 89 290 12 198

Fax +49 89 290 12 222

LanguagesEnglish, French, German

Practice groupCorporate & Finance

Jörg Schickert possesses extensive experience handling complex regulatory and transactional matters across the pharmaceutical and medical devices industries including pricing, licensing and compliance.

Who's Who, 2019

If you work in the pharma, medical devices or biotech sector, it is Jörg Schickert who will be solving all your most complicated regulatory, commercial and compliance issues – for both Germany and all of Europe. His long-standing experience in dealing with German and European pharmaceutical and devices law means that he can circumspectly navigate you through all your reimbursement or pricing and reimbursement challenges. He will also aid you in drafting commercial/licensing contracts. Furthermore, you may turn to him with any most delicate criminal and compliance cases which your company might face. Jörg is very practical and always offers business-oriented solutions. He takes his industry knowledge from 15 years' experience in working hand-in-hand with many major and reputed life sciences companies.

Jörg is one of the few go-to lawyers in Europe for complex issues in the core business of the life sciences industry. He has a deep knowledge across all relevant legal areas of the day-to-day business of selling pharmaceutical products and devices or offering health solutions. This allows him to provide overall solutions for issues and projects which have implications in very different legal disciplines, such as regulatory, reimbursement, commercial, and compliance. He advises on reimbursement strategies, clinical trials, the launch and marketing of new products, dealing with health care professionals, anti-corruption/transparency, product safety and vigilance and related agreements and contracts. He also assists our corporate teams in transactions pertaining to the life science industry.Most recently, his life sciences industry team was named the Best Lawyers™ "Law firm of the year for pharmaceutical law" in Germany for the 2018 edition. The team is ranked in band 1 by JUVE, Chambers Global/Europe and LMG Germany, in 2017 as well as in preceding years.

Awards and recognitions

2018-2020

Acritas Star
Acritas Stars Independently Rated Lawyers

2007-2020

Frequently recommended lawyer for pharmaceutical and medical device law
JUVE handbook

2018-2019

Industry Focus: Healthcare and Life Sciences, Leading Individual
Legal 500

2014-2019

Trade and Distribution, Leading Lawyer
Legal 500

2009-2020

Included for Health Care
Edition Best Lawyers™ in German

2011-2019

Notable Practitioner
Chambers Europe

2012-2020

Leading name for pharmaceutical and medical device law
JUVE handbook

2012-2020

Frequently recommended Lawyer for Distribution Law
JUVE handbook

2018-2020

Frequently mentioned Lawyer for Pharmaceutical and drug law
Kanzleimonitor

2013-2020

Included for Regulatory Practice and Pharmaceuticals law
Edition Best Lawyers™ in Germany

2019

Recommended Lawyer for Life Sciences
Who's Who

Education and admissions

Education

Second State Exam in Law, Higher Regional Court of Nuremberg, 2001

Dr. iur., Friedrich-Alexander University Erlangen-Nürnberg, 2000

First State Exam in Law, Friedrich-Alexander University Erlangen-Nürnberg, 1996

Representative experience

Advising a leading pharmaceutical company on its innovative approach re digital health solutions alongside its pharma product offering in 21 countries on 4 continents.

Advising a U.S. medical devices company on regulatory and commercial issues regarding the market launch of a gene test in 24 European countries.

Due diligence and advising the Spanish pharma company Esteve on its sale and purchase agreement regarding its acquisition of Riemser Pharma

Advising MorphoSys Ag in the drafting and negotiating of an agreement regarding the co-development and co-marketing as well as the out-licensing (ex-US) of its blood cancer product

Reimbursement advice regarding the (aut idem) substitution in the pharmacy and reference price groups concerning an active ingredient complex and biologic pharmaceuticals.

Strategic and on-going HCP compliance advice as well as compliance audit of US-based  pharmaceutical company.

Loading data